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A B ST R AC T 
 
 
Prostate cancer represents the leading malignant tumor in men over 50 years 
of age with 400,000 new cases being diagnosed yearly in Europe. Even if 
the incidence rate is higher than the mortality rate, still there is an increasing 
trend when speaking of its mortality. The increasing incidence of the 
metabolic syndrome, the unhealthy lifestyle, the high lipid and Calcium 
intake, the high spread of infections with Human Papilloma Virus, Human 
Herpes Virus, the excess of androgen consumption and the longer life 
expectancy, are few of the main causes of prostate cancer increasing 
incidence. The new systemic therapies such as immunotherapy with 
Checkpoint Inhibitors or Poly, ADP-Ribose Polymerase inhibitors and local 
experimental procedures addressing tumor destruction, such as High-
Intensity Focused Ultrasound, the Cryo and Focal Laser Ablation, provide 
good outcomes and become new promising tools for prostate cancer therapy. 
Physicians consider these methods worth using; the efficacy of some specific 
categories of patients being arguments for their use in the current protocols 
even though solid data regarding the improvement of global mortality rates 
are not yet published. The current article focuses on the newest systemic and 
local experimental treatment tools highlighting their benefits, especially for 
hormone-resistant prostate cancer.   
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Prostate cancer represents the leading malignant 
tumor and the third cause of death in men over 50 years 
of age. Around 1.6 million new cases of prostate cancer 
are diagnosed worldwide, while 400,000 new cases are 
diagnosed yearly only in Europe [1-3]. The incidence 
looks to have an increasing pattern with a percentage 
between 2 to 8/ year, and it increases with age. Even if 
the incidence rate is higher than the mortality rate, still 
there is an increasing trend when speaking about prostate 
cancer mortality lately, especially in androgen resistant 
tumors. The increasing incidence of obesity, diabetes 
mellitus, hypercholesterolemia, the unhealthy lifestyle, 
alcohol abuse, the high lipid and Ca intake, the high 
spread of infections with Human Papilloma Virus (HPV), 
Human Herpes Virus (HHV) or other sexually transmitted 
infections, the excess of androgen consumption and the 
longer life expectancy due to the decrease in mortality 
rates secondary to cardiovascular diseases, are few of the 
main causes for the increasing incidence of prostate 
cancer [4,5]. The stage of diagnosis changed during the 
last decade, the screening methods based on the 
widespread use of prostate specific antigen (PSA) testing 
have improved the mortality rates. The prolonged 
survival is related to the detection of prostate cancer in 
the early stages, secondary to screening global appliance. 
However, the difficulty in differentiating between 
clinically indolent prostate cancers, usually less 
symptomatic or even asymptomatic, and more aggressive 
types, with lethal potential still remaining a problem. On 
this background, the Gleason grading remains the best 
prognostic indicator, even if cases with morphologically 
similar structures can behave differently. New 
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approaches such as DNA microarray technology and the 
research results coming from the proteomics field made 
substantial discoveries for a better understanding of the 
pathogenesis of human cancer. Understanding the genetic 
changes underlying the onset, development, and 
progression of prostate malignant tumors made room for 
new therapeutic options. The discoveries of the prostate 
cancer molecular fingerprints will help physicians better 
classify patients according to the evolution pattern. The 
research resources are nowadays targeting cancers with 
poor prognoses [6-7]. The new systemic therapies such as 
immunotherapy with check point inhibitors (CPi) or Poly 
ADP-Ribose Polymerase inhibitors (PARPi) and local 
experimental procedures addressing tumor destruction 
provide good outcomes and are present in the current 
treatment protocols, even if some of these procedures are 
not yet considered gold standard. Besides the systemic 
therapies, the High-Intensity Focused Ultrasound (HIFU), 
the Cryo and Focal Laser Ablation are promising tools used 
in prostate cancer therapy. The following article presents the 
newest treatment options for prostate cancer, especially for 
cases of androgen-resistant tumors [8,9]. 
Discussions 
The Immune Checkpoint Inhibitor therapy (CPi) and 
Poly ADP-Ribose Polymerase inhibitors (PARPi) 
In the last few years, immunotherapy has been 
successful and proved to be a very effective treatment 
option in a variety of cancers [5]. Even though the efficacy 
of immune checkpoint blockade in the prostate cancer 
treatment looks promising, it still needs some 
clarifications. The latest clinical trials in the field support 
the theory according to which certain genetic mutations 
such as microsatellite instability/mismatch repair gene 
deficiency may increase the susceptibility to immune 
checkpoint blockade [10,11].  
In general, the immune response acts against cancer 
occurrence by an active succession of immune events such 
as realization and presentation of tumor-associated 
antigens (TAA), activation and local infiltration with 
cytotoxic T-lymphocytes, and ultimately recognition and 
destruction of cancer cells. It seems that the loss of cancer-
specific immune-dominant epitopes, the T cell priming and 
activation, the inefficient TAA processing and 
presentation, along with the local immunosuppressive 
microenvironment may produce immune tolerance to TAA 
[5,12]. Based on this evidence, the immune CPi therapy 
reactivates and enhances anticancer immunity by blocking 
negative co-stimulatory molecules such as programmed 
cell death-1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4). The PD-1/PD-L1 blockade 
such as nivolumab or pembrolizumab downregulates 
glycolysis, the metabolism of amino acid and fatty acid 
oxidation, as well as cell proliferation. The anti-CTLA-4 
class (ipilimumab) promotes the abundance of T 
lymphocytes in the microenvironment enhancing the 
immune response. Furthermore, the anticancer efficacy of 
the immune CPI can be boosted by synergic poly ADP-
ribose polymerase (PARP) inhibition, the additive effects 
of this class inducing finally the synthetic lethal effect in 
cancer cells. Along with the immune CPI, numerous 
PARPis have been lately developed. Veliparib, rucaparib, 
olaparib, niraparib, and talazoparib are nowadays studied 
for their efficacy in ovarian, breast, pancreatic, lung and 
bladder cancer therapy based on their up-regulation of gene 
mutations, repairing the DNA damage accumulation and 
promoting the tumor cell death [13-16].  
However, prostate cancer seems to act a bit differently 
compared to other solid cancers, and only a minority of 
patients show sensitivity to the immune therapy. The 
“Immune Checkpoint Blockade for Prostate Cancer: Niche 
Role or Next Breakthrough?” session presented at the 
ASCO 2020, promotes the hypothesis according to which 
identifying specific biomarkers to predict the response to 
PD-1/PD-L1 blockade and combine CPi with other 
treatments seems a possible approach to optimize the 
outcomes in prostate cancer. Combining PARPi and 
immune CPi in prostate cancer patients looks rational due 
to their mechanisms of action. PARPi promote the release 
of damaged DNA into the cytosol, also promote the 
activation of the immune pathway called cGAS–STING 
and the release of TAA and, furthermore, as in breast 
cancer, PARP inhibition may upregulate PD-L1 [17-19].  
The current evidence on this line is a phase II trial 
testing olaparib plus durvalumab in men castration-
resistant prostate cancer which proved that 50% of the 
patients had an imaging and serologic response. Still, 
approximately 66% of the responders had microsatellite 
instability, indicating that this combination could be 
effective only in tumors with such defects [19,20]. More 
upcoming data will assure clinicians about the benefits of 
CPi and PRAPi combination common usage in specific 
categories of patients and will probably become standard 
approaches in prostate cancer therapy. In addition, the 
combinations of antiandrogen therapy with CPI, cytokine 
inhibitors, vaccines and specific T-cell engagers seem to 
provide new horizons for metastatic or non-metastatic 
castration resistant prostate cancers [19-22].  
Local experimental procedures. 
In terms of local ablative procedures for prostate 
cancer, these methods are usually addressed to localized 
small tumors when radical prostatectomy is not applicable 
or as adjuvant or palliative treatments in case of recurrence 
or resistance to standard treatments. HIFU, cryotherapy 
and focal laser ablation are suitable methods to use as 
monotherapy or in combination with the current 
standardized treatments.  
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a) High-Intensity Focused Ultrasound (HIFU) 
designated to treat localized, locally advanced or recurrent 
prostate cancer uses high-intensity sound waves to heat up 
to 90 degrees C (194 degrees F) and destroy the prostate 
cancer cells. Under anesthesia, the US probe is fixed in the 
rectum and 2 crystals transmit the image to the computer 
and back to the gland in order to target the abnormal tissue. 
In this way, the normal prostate tissue is protected and 
HIFU seems to have greater success in studies, fewer side 
effects than reported in surgery or radiotherapy. Urinary 
incontinence, infection, prostate swelling and erectile 
dysfunction can occur in some cases. Clinical trials provide 
optimism in this direction [23-26]. 
b) Opposed to HIFU, cryotherapy freezes prostate cancer 
cells in order to destroy them and uses an argon-based 
machine. Its usage is reserved especially for disease 
recurrence or as an alternative to other options. The 
procedure is done under general or spinal anesthesia. 
Under US guidance, small tubular probes are inserted 
through the perineum into the prostate tissue and cold gases 
(nitrogen liquid, argon) are passed inside the gland. The US 
helps the physician avoid the normal tissue destruction. 
During the procedure, warm water is inserted through a 
urethral catheter to avoid its damage and it is left there for 
a few days [27-29]. Prostate targeted cryoablation (TCAP) 
is equal in efficacy or surpasses the morbidity produced by 
other standardized local procedures such as brachytherapy, 
external-beam radiation or three-dimensional beam 
radiation.  Erectile dysfunction is present as a side effect in 
almost all cases (93%). Urinary incontinence (7.5%), and 
very rarely, the formation of rectal fistulae (0.5-1%) are 
observed [30-32]. TCAP provides a long-term, durable 
response with regard to disease control according to 
clinical trial results. Fewer positive biopsies were 
documented after cryoablation than after radiotherapy 
[33,34].  
c) Focal Laser Ablation (FLA) is an alternative treatment 
for prostate cancer patients not yet standardized by 
guidelines. It is suitable for patients in whom radical 
prostatectomy or radiation are not considered as optimal 
therapy. The MRI guidance helps the physician fix the laser 
fiber into the tumor [34-36]. The energy flowed into the 
fiber will heat the tumor cells and will destroy them. The 
procedure is quick, safe, the patient’s discomfort is 
minimal and the procedure itself does not require hospital 
admission. It is done under local anesthesia and mild 
sedation and can be repeated several times [35-37]. The 
procedure involves few side effects such as erectile 
dysfunction, urinary incontinence, or bowel problems, 
especially if the tumor is located in the proximity of the 
nerves responsible for the erectile function, innervate the 
urethra, or the rectal wall. Clinical trials have proven that 
the morbidity percentages are much lower than in other 
ablative procedures [36-38]. 
Highlights 
✓ Prostate cancer still poses difficulties in predicting the 
evolution pattern. 
✓ Research focused on proteomics provides new therapy 
approaches on cancer in general and on prostate 
cancer, in particular. 
✓ Immunotherapy with Immune Checkpoint Inhibitor 
therapy (CPi) and Poly ADP-Ribose Polymerase 
inhibitors (PARPi) seem to improve difficult-to-treat 
types of prostate cancer. 
✓ Local ablative techniques using imaging guidance 
improve not only the outcome of patients, but 
positively influence their ECOG (Eastern Cooperative 
Oncology Group) performance status. 
Conclusions 
The continuous and effervescent research in the field of 
oncology came with the development of new classes of 
drugs, such as immunotherapy, providing new horizons 
and better outcomes, especially for antiandrogen resistant 
prostate cancer patients. Along with the local ablative 
procedures such as HIFU, TCAP and FLA, 
immunotherapy with CPi and PRAPi, not only prolong life 
expectancy, but also improve the quality of life and reduce 
morbidity rates in prostate cancer patients.  
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